NVO vs NVS

Novo Nordisk A/S and Novartis AG, both Healthcare

Novartis AG is the larger company at $281B against $191B. Over the past year NVS returned +40% against +1.5% for NVO. Ryufin's sector-relative Smart Score puts NVO ahead, 9/10 against 8/10.

Novo Nordisk A/S and Novartis AGcompared on valuation, return and Ryufin’s Smart Score
FigureNVONVS
Last close$47.19$158
Market cap$191B$281B
Trailing P/Elower is cheaper for the same earnings, not automatically bettern/a23.3
1-year return+1.5%+40%
5-year return+13%+106%
Ryufin Smart Scoresector-relative, 1–109/108/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Novartis AG

Revenue of $27B in H2 2025, net income $6.3B.

NVS overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or read the correlation.